Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.
2 Breakout Growth Stocks to Buy for the Long Haul
These two healthcare stocks have crushed the broader markets this year.